Evidence map›Paper›PMID 35755512›Full record

ArticleCureus2022

Myopericarditis After mRNA COVID-19 Vaccine in a Patient With Recent History of COVID-19.

Eiman Elhouderi, Eman Elsawalhy, Mohamed Kabbani

Abstract readCase Reports
In one paragraph

Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Eiman ElhouderiInternal Medicine, Beaumont Health, Dearborn, USA.
Eman ElsawalhyInternal Medicine, Beaumont Health, Dearborn, USA.
Mohamed KabbaniInternal Medicine, Beaumont Health, Dearborn, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myopericarditis has been identified as a potential adverse event of several vaccines in the medical literature. Here we present a case of a 30-year-old male who had myopericarditis a week after receiving the second booster dose of the Pfizer-BioNTech coronavirus disease 2019 (COVID-19) vaccine. The patient's clinical course was not severe and had a full recovery after a week of treatment.

Indexed as

covid-19 infectioncovid-19 vaccinem-rna vaccinemyocarditispericarditis

Identifiers

PMID35755512
PMCPMC9224764

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.